🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
You are recommended to avoid alcohol consumption if you are being treated with Actemra 80mg/4ml IV Infusion. Alcohol intake, along with Actemra 80mg/4ml IV Infusion, may cause increased dizziness and risk of stomach bleeding/ulcers.
Actemra 80mg/4ml IV InfusionN is not recommended for use in pregnant women unless clearly necessary. Women of childbearing potential must use effective contraception during and up to 3 months after> management. Contact your doctor before receiving Actemra 80mg/4ml IV Infusion.
Actemra 80mg/4ml IV Infusion is not recommended for use in breastfeeding mothers as it is not known if it is excreted in the breast milk. Leave a gap of at least 3 months after your last management before starting breastfeeding. Consult your doctor before receiving Actemra 80mg/4ml IV Infusion.
Do not drive or operate any machines if you feel dizzy after receiving Actemra 80mg/4ml IV Infusion.
Actemra 80mg/4ml IV Infusion should be used with caution in patients with mild to moderate kidney disease with no dose adjustment. There is no information available on the use of this medicine in severe kidney disease. Consult your doctor before receiving Actemra 80mg/4ml IV Infusion.
Actemra 80mg/4ml IV Infusion is not recommended in patients with active liver disease or liver impairment. Consult your doctor before receiving Actemra 80mg/4ml IV Infusion.
Treatment of Rheumatoid arthritis, Ankylosing spondylitis, and giant cell arteritis.
Actemra 80mg/4ml IV Infusion works by blocking the activity of a specific protein (cytokine) called interleukin 6, which is involved in inflammatory processes of the body, and blocking it can reduce the pain and swelling in your joints.
Actemra 80mg/4ml IV Infusion contains Tocilizumab which belongs to the group of medicines called interleukin-6 (IL-6) receptor inhibitors. It is used to manage adults with moderate to severely active rheumatoid arthritis (an inflammatory disease affecting the joints).
Tocilizumab is a humanized monoclonal antibody that targets and inhibits the interleukin-6 (IL-6) receptor, which is part of the immunoglobulin IgG1K subclass. By binding to both soluble and membrane-bound IL-6 receptors, Tocilizumab effectively blocks IL-6-mediated signaling. IL-6 is a key pro-inflammatory cytokine produced by various cells, including T-cells, B-cells, monocytes, and fibroblasts. It plays a significant role in immune system functions like T-cell activation, antibody production, liver protein synthesis, and blood cell formation. Additionally, IL-6 is involved in local inflammatory processes in the joints, contributing to conditions like rheumatoid arthritis.
Preparation:
Administration:
|
Preparation:
Administration:
|
Rheumatoid Arthritis:
- IV Infusion:
- Start with 4 mg/kg every 4 weeks.
- May increase to 8 mg/kg every 4 weeks based on clinical response.
- Maximum dose: 800 mg per infusion.
- SC Injection:
- Weight < 100 kg: 162 mg SC every other week, increasing to every week based on clinical response.
- Weight > 100 kg: 162 mg SC every week.
Hepatic Impairment:
- Not recommended in patients with active hepatic disease or hepatic impairment.
Systemic Juvenile Idiopathic Arthritis (SJIA):
- < 2 years: Safety and efficacy not established.
- > 2 years:
- Weight < 30 kg: 12 mg/kg IV every 2 weeks.
- Weight > 30 kg: 8 mg/kg IV every 2 weeks.
- Can be administered as monotherapy or with methotrexate.
Polyarticular Juvenile Idiopathic Arthritis (PJIA):
- < 2 years: Safety and efficacy not established.
- > 2 years:
- Weight < 30 kg: 10 mg/kg IV every 4 weeks.
- Weight > 30 kg: 8 mg/kg IV every 4 weeks.
- Can be administered as monotherapy or with methotrexate.
- Mild Renal Impairment: No dosage adjustment is required.
- Moderate-to-severe renal Impairment: Has not been studied.
Drug-Drug Interactions:
Drug-Food Interaction:
Drug-Disease Interactions:
Tocilizumab is contraindicated in patients with known hypersensitivity to Tocilizumab.
Based on animal data, may cause fetal harm. In case of COVID-19, Tocilizumab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus. Discontinue drug or nursing taking into consideration importance of drug to mother. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.